Physician profile
Daniel E Hardy
NPI 1689679045
$2,025.57
in general payments reported to CMS, 2019-2025
17 companies · $719 in 2025
The $719 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.31 · 2020: $81.73 · 2021: $453 · 2022: $240 · 2023: $120 · 2024: $393 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.87 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $510.51 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $315.95 | 2020-2024 | Farxiga |
| Novo Nordisk INC | $277.54 | 2021-2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.64 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $178.15 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Corcept Therapeutics | $101.88 | 2024-2025 | Korlym |
| Amgen INC. | $80.46 | 2024-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $78.85 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.75 | 2021-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $48.85 | 2024-2025 | Rexulti |
| Eisai INC. | $25.97 | 2025 | |
| Astellas Pharma US INC | $23.77 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $19.62 | 2023 | |
| Dexcom, INC. | $17.41 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $15.81 | 2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $14.85 | 2025 | The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.